BPC-157 is most often considered when: Recovery from a musculoskeletal injury has stalled beyond the expected timeline Inflammation appears to be a persistent driver rather than an acute protective response Gut lining integrity is a concern as part of a broader inflammatory or digestive picture The patient is a reasonable candidate for physician-supervised peptide therapy based on health history and risk profile It is not appropriate when there is an unresolved structural question that imaging should answer first, when there are acute red flag symptoms warranting urgent evaluation, or when the individual is hoping a peptide will substitute for rehabilitation and load management
Research suggests MOTS-c may mimic effects of exercise by activating AMPK pathways
20 doses at 250mcg, 14 doses at 350mcg, or 10 doses at 500mcg
These include Metformin, oral contraception, proton pump inhibitors, H2 receptor antagonists, antibiotics, and aspirin
Those peptides being marketed for longevity or performance have not been rigorously studied in human trials or approved by the FDA, says Kumar